Cargando…

Pulmonary metastasis secondary to abiraterone‐resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case

INTRODUCTION: Most metastatic prostate cancers acquire the capacity for androgen‐independent growth and become resistant to androgen deprivation therapy. A patient‐focused treatment strategy is needed for aggressive castration‐resistant prostate cancer. CASE PRESENTATION: We report the case of a 62‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izawa, Mizuki, Kosaka, Takeo, Nakamura, Kohei, Oba, Junna, Hishida, Tomoyuki, Hongo, Hiroshi, Mikami, Shuji, Nishihara, Hiroshi, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784740/ https://www.ncbi.nlm.nih.gov/pubmed/33426488 http://dx.doi.org/10.1002/iju5.12224

Ejemplares similares

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion
por: Shojo, Kazunori, et al.
Publicado: (2021)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report
por: Umeda, Kota, et al.
Publicado: (2020)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review
por: Masuda, Tsukasa, et al.
Publicado: (2022)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
por: Kosaka, Takeo, et al.
Publicado: (2019)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan
por: Kobayashi, Hiroaki, et al.
Publicado: (2021)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Genomic analysis of aggressive ductal adenocarcinoma of the prostate
por: Kobayashi, Hiroaki, et al.
Publicado: (2022)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
por: Kamisawa, Ken, et al.
Publicado: (2019)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2021)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling
por: Ueki, Arisa, et al.
Publicado: (2021)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Estimating copy number using next-generation sequencing to determine ERBB2 amplification status
por: Nakamura, Kohei, et al.
Publicado: (2021)

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer
por: Hagiwara, Masayuki, et al.
Publicado: (2018)

Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer
por: Takayama, Ken-ichi, et al.
Publicado: (2021)

Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy
por: Mizuno, Ryuichi, et al.
Publicado: (2022)

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel
por: Kosaka, Takeo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_atjojsfre1v74lea83vm84mtq7